SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yu Chen-Ming

(Last)

(First)

(Middle)

C/O SAGENT PHARMACEUTICALS, INC.

1901 NORTH ROSELLE ROAD, SUITE 700

(Street)

SCHAUMBURG

60195

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/19/2011

3. Issuer Name and Ticker or Trading Symbol
Sagent Holding Co. [ SGNT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock⁽¹⁾	1,275,868	I	See Footnote⁽²⁾
Common Stock⁽³⁾	7,685,584	I	See Footnote⁽⁴⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option to Buy	⁽⁵⁾	08/15/2018	Common Stock	12,758	$4.23	D

Explanation of Responses:

1. Represents shares of Common Stock deemed beneficially owned by the undersigned on account of the automatic conversion of its 10,000,001 ordinary shares of Sagent Holding Co., a Cayman Islands company, in connection with the Reincorporation, and the related one-for-7.8378 reverse stock split to be implemented in connection therewith. The Reincorporation will become effective prior to the closing of the initial public offering.

2. The shares reported are held of record collectively by Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P. (the "Vivo V Funds"). Dr. Yu is a partner of Vivo Ventures. As a result, Dr. Yu may be deemed the beneficial owner of the shares of common stock owned collectively by the Vivo V Funds. Dr. Yu hereby disclaims any beneficial ownership of any shares directly held by the Vivo V Funds, except to the extent of his pecuniary interest therein.

3. Represents shares of Common Stock deemed beneficially owned by the undersigned on account of the automatic conversion of its 60,238,097 Series A preference shares of Sagent Holding Co., a Cayman Islands company, in connection with the Reincorporation, and the related one-for-7.8378 reverse stock split to be implemented in connection therewith. The Reincorporation will become effective prior to the closing of the initial public offering.

4. The shares reported are held of record collectively by Vivo Ventures Fund V, L.P., Vivo Ventures V Affiliates Fund, L.P., Vivo Ventures Fund VI, L.P. and Vivo Ventures VI Affiliates Fund, L.P. (the "Vivo Funds"). Dr. Yu is a partner of Vivo Ventures. As a result, Dr. Yu may be deemed the beneficial owner of the shares of common stock owned collectively by the Vivo Funds. Dr. Yu hereby disclaims any beneficial ownership of any shares directly held by the Vivo Funds, except to the extent of his pecuniary interest therein.

5. Stock option granted on August 15, 2008 and vests 25% per year over four years.

	/s/ Chen-Ming Yu	04/19/2011
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.